Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes

JACC: Basic to Translational Science

Volumn 1, Issue 3, 2016, Pages 143-154

  Takemoto, Yoshio ^a   Ramirez, Rafael J ^a   Yokokawa, Miki ^a   Kaur, Kuljeet ^a   Ponce Balbuena, Daniela ^a   Sinno, Mohamad C ^a   Willis, B Cicero ^a   Ghanbari, Hamid ^a   Ennis, Steven R ^a   Guerrero Serna, Guadalupe ^a   Henzi, Bettina C ^a   Latchamsetty, Rakesh ^a   Ramos Mondragon, Roberto ^a   Musa, Hassan ^a   Martins, Raphael P ^a   Pandit, Sandeep V ^a   Noujaim, Sami F ^b   Crawford, Thomas ^a   Jongnarangsin, Krit ^a   Pelosi, Frank ^a   Bogun, Frank ^a   Chugh, Aman ^a   Berenfeld, Omer ^a   Morady, Fred ^a   Oral, Hakan ^a   Jalife, José ^a   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

atrial fibrillation; catheter ablation; fibrosis; galectin 3; upstream therapy

Indexed keywords

EID: 85010443418     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2016.03.003     Document Type: Review

References (43)

1. 1 Burstein, B., Nattel, S., Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51 (2008), 802–809.
2. 2 MacKinnon, A.C., Farnworth, S.L., Hodkinson, P.S., et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 180 (2008), 2650–2658.
3. 3 Henderson, N.C., Mackinnon, A.C., Farnworth, S.L., et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172 (2008), 288–298.
4. 4 Traber, P.G., Zomer, E., Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One, 8, 2013, e83481.
5. 5 Yu, L., Ruifrok, W.P., Meissner, M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6 (2013), 107–117.
6. 6 Ho, J.E., Liu, C., Lyass, A., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60 (2012), 1249–1256.
7. 7 Ahmad, N., Gabius, H.J., Andre, S., et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 279 (2004), 10841–10847.
8. 8 Mackinnon, A.C., Gibbons, M.A., Farnworth, S.L., et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 185 (2012), 537–546.
9. 9 Schmierer, B., Hill, C.S., TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8 (2007), 970–982.
10. 10 Wu, X.Y., Li, S.N., Wen, S.N., et al. Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease. Europace 17 (2015), 1541–1547.
11. 11 Kornej, J., Schmidl, J., Ueberham, L., et al. Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS One, 10, 2015, e0123574.
12. 12 Martins, R.P., Kaur, K., Hwang, E., et al. Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation. Circulation 129 (2014), 1472–1482.
13. 13 Miller, M.C., Klyosov, A.A., Mayo, K.H., Structural features for alpha-galactomannan binding to galectin-1. Glycobiology 22 (2012), 543–551.
14. 14 Lin, Y., Chiu, Y., Shiau, Y., et al. The relation between serum level of amioterminal propeptide of type I procollagen and diastolic dysfunction in hypertensive patients without diabetes mellitus: a pilot study. J Hum Hypertens 20 (2006), 964–967.
15. 15 Gray, R.A., Pertsov, A.M., Jalife, J., Spatial and temporal organization during cardiac fibrillation. Nature 392 (1998), 75–78.
16. 16 Schmalhofer, W.A., Swensen, A.M., Thomas, B.S., et al. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-a-go-go related gene potassium channel. Assay Drug Dev Technol 8 (2010), 714–726.
17. 17 Pandit, S.V., Zlochiver, S., Filgueiras-Rama, D., et al. Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs. Cardiovasc Res 89 (2011), 843–851.
18. 18 Grandi, E., Pandit, S.V., Voigt, N., et al. Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation. Circ Res 109 (2011), 1055–1066.
19. 19 Gurses, K.M., Yalcin, M.U., Kocyigit, D., et al. Effects of persistent atrial fibrillation on serum galectin-3 levels. Am J Cardiol 115 (2015), 647–651.
20. 20 Henry, W.L., Morganroth, J., Pearlman, A.S., et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 53 (1976), 273–279.
21. 21 Zou, R., Kneller, J., Leon, L.J., Nattel, S., Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. Am J Physiol Heart Circ Physiol 289 (2005), H1002–H1012.
22. 22 Acevedo, M., Corbalan, R., Braun, S., Pereira, J., Navarrete, C., Gonzalez, I., C-reactive protein and atrial fibrillation: “evidence for the presence of inflammation in the perpetuation of the arrhythmia”. Int J Cardiol 108 (2006), 326–331.
23. 23 Gedikli, O., Dogan, A., Altuntas, I., et al. Inflammatory markers according to types of atrial fibrillation. Int J Cardiol 120 (2007), 193–197.
24. 24 Henderson, N.C., Mackinnon, A.C., Farnworth, S.L., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 103 (2006), 5060–5065.
25. 25 Liu, Y.H., D'Ambrosio, M., Liao, T.D., et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 296 (2009), H404–H412.
26. 26 Blanchard, H., Yu, X., Collins, P.M., Bum-Erdene, K., Galectin-3 inhibitors: a patent review (2008-present). Expert Opin Ther Pat 24 (2014), 1053–1065.
27. 27 Traber, P.G., Chou, H., Zomer, E., et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One, 8, 2013, e75361.
28. 28 Schultz Jel, J., Witt, S.A., Glascock, B.J., et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109 (2002), 787–796.
29. 29 Fujiu, K., Nagai, R., Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol 70 (2014), 64–73.
30. 30 Rosenkranz, S., TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63 (2004), 423–432.
31. 31 Petrov, V., Fagard, R., Lijnen, P., Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 39 (2002), 258–263.
32. 32 Lin, Y.T., Chen, J.S., Wu, M.H., et al. Galectin-1 accelerates wound healing by regulating the neuropilin-1/Smad3/NOX4 pathway and ROS production in myofibroblasts. J Invest Dermatol 135 (2015), 258–268.
33. 33 Ashihara, T., Haraguchi, R., Nakazawa, K., et al. The role of fibroblasts in complex fractionated electrograms during persistent/permanent atrial fibrillation: implications for electrogram-based catheter ablation. Circ Res 110 (2012), 275–284.
34. 34 Voigt, N., Trausch, A., Knaut, M., et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol 3 (2010), 472–480.
35. 35 Greiser, M., Kerfant, B.G., Williams, G.S., et al. Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. J Clin Invest 124 (2014), 4759–4772.
36. 36 Christ, T., Rozmaritsa, N., Engel, A., et al. Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation. Proc Natl Acad Sci U S A 111 (2014), 11193–11198.
37. 37 Pricci, F., Leto, G., Amadio, L., et al. Role of galectin-3 as a receptor for advanced glycosylation end products. Kidney Int Suppl 77 (2000), S31–S39.
38. 38 Thornhill, W.B., Wu, M.B., Jiang, X., Wu, X., Morgan, P.T., Margiotta, J.F., Expression of Kv1.1 delayed rectifier potassium channels in Lec mutant Chinese hamster ovary cell lines reveals a role for sialidation in channel function. J Biol Chem 271 (1996), 19093–19098.
39. 39 Lennarz, W., Role of intracellular membrane systems in glycosylation of proteins. Methods Enzymol 98 (1983), 91–97.
40. 40 Huang, C.L., Regulation of ion channels by secreted Klotho: mechanisms and implications. Kidney Int 77 (2010), 855–860.
41. 41 Mason, A.K., Jacobs, B.E., Welling, P.A., AP-2-dependent internalization of potassium channel Kir2.3 is driven by a novel di-hydrophobic signal. J Biol Chem 283 (2008), 5973–5984.
42. 42 Choi, W.S., Khurana, A., Mathur, R., Viswanathan, V., Steele, D.F., Fedida, D., Kv1.5 surface expression is modulated by retrograde trafficking of newly endocytosed channels by the dynein motor. Circ Res 97 (2005), 363–371.
43. 43 Partridge, E.A., Le Roy, C., Di Guglielmo, G.M., et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306 (2004), 120–124.